Lidocaine (GMP)

Overview

Lidocaine (GMP) is Lidocaine ( HY-B0185 ) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.

Application

Products | Products > GMP Small Molecules | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Sodium Channel | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > ERK | Products > Signaling Pathways > MEK

Product Information

• Catalog No.: HY-B0185G
• CAS No.: 137-58-6
• Molecular Formula: C14H22N2O
• Molecular Weight: 234.34
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source